0
CZ Veterinaria (CZV) and Boehringer Ingelheim Animal Health announced today that both companies have entered into a cooperation to provide Entericolix®, an innovative sow vaccine, to the European swine vaccine market. CZV has developed and registered Entericolix® in Europe; Boehringer Ingelheim Animal Health will use its strong swine distribution network and technical support to provide the vaccine to customers.
The European National Authorities have approved Entericolix® which is unique in providing a 21 days duration of immunity against diarrhoea in piglets caused by E. coli. and C. perfringens Type C.
The vaccine reduces mortality and clinical signs caused by E. coli neonatal diarrhoea and Necrotic Enteritis. Entericolix® has the unique claim of extending this protection to piglets until 21 days of age, even after the pigs were weaned. Furthermore, it provides protection against early onset of Oedema Disease caused by F18 E. coli up to 28 days of age (7 days after weaning). Oedema Disease is a naturally occurring post weaning piglet disease seen after infection with certain strains of E. coli that can lead to neurological signs and death.
The Entericolix© vaccine has been successfully registered through the decentralized procedure in 20 European countries. Andrés Fernandez, CEO of CZV, stated,"This new approval of Entericolix© is an important milestone for CZV, which contributes to our goal of developing and manufacturing vaccines for the prevention of animal diseases. This vaccine also increases our livestock portfolio, particularly for swine. This new agreement builds on the great strengths of Boehringer Ingelheim Animal Health as an expert in enteric swine diseases.”
Dr. Erick Lelouche, Head of Global Marketing at Boehringer Ingelheim Animal Health, commented: “Entericolix© is a very innovative vaccine which perfectly supports our goal of strengthening our vaccine line for enteric diseases, thus providing additional value to customers in Europe”.
Dr. Jorge Blanco, Professor and Head of LREC-USC, is convinced that the only effective way of protection against porcine colibacillosis is through the use of vaccines, since most porcine enteropathogenic E. coli strains are multidrug-resistant.
Specific details of the agreement were not disclosed. Entericolix© is a trade mark of CZ Veterinaria.
July 21, 2016 - Boehringer
